Rimon
Save as PDF RSS Feed Subscribe

Entries tagged “Start-ups”

Princeton Entrepreneurship Council’s Startup Workshop: Legal Considerations for Startups

Event
May 31, 2019 10:00AM - 10:55AM EDT

Add to iCal/Outlook

Date & Time May 31st, 2019, 10am Why You Should Attend Rimon’s FinTech Partner, Dror Futter, will be speaking at Princeton Entrepreneurship Council's "Startup Workshop: Legal Considerations for Startups. Register here Dror Futter is a partner in the Rimon, PC law firm. Dror's practice focuses on representing startup

Continue Reading…

Blockchain and Money Transmission: A New Horizon for Token-Driven Startups?

Insight Sam Miller Sam Miller · April 09, 2019
Tokens, security tokens, cryptocurrency, or however you wish to define the digital asset which distributed ledger technology has now allowed us to pull from ether, puts issuers and exchangers of this value within the cross-hairs of both Federal and State money transmitter regulation. The question becomes then whether token-driven blockchain

Continue Reading…

Rimon Partners John Isaza and Yaacov Silberman to present at LegalTech West Coast

Event
Jul 13, 2015

Add to iCal/Outlook

Two Rimon Partners will be presenting at the upcoming Legaltech West Coast conference, to take place on July 13-14, 2015 in San Francisco, CA. LegalTech is a premier legal technology conference hosted by ALM Media. John Isaza, FAI, will participate in a panel titled "The New Big Bang: 21st Century Information Governance Challenges". The panel features

Continue Reading…

Rimon’s Robert Lee featured in Korean Broadcasting System’s documentary on Silicon Valley and the future of startups

Insight December 15, 2014
Rimon's Robert Lee on Korean Broadcasting Systems Documentary on Silicon Valley and the Future of Startups

Continue Reading…

Corporate Governance in the Lifecycle of a Pre-Sales Revenue Biotechnology Venture Destined for IPO Success

Insight Mark H. Mirkin Mark H. Mirkin · August 14, 2014
So how do biotech ventures govern themselves to run efficiently while complying with state corporate law statutes and state and federal securities laws and regulations imposed by stock exchanges? Frugality that is often self-imposed by scientific founders and then endorsed by the angel investors and venture capital company investors that follow

Continue Reading…

Capital Structure Particulars in the Lifecycle of a Pre-Sales Revenue Biotechnology Venture Destined for IPO Success

Insight Mark H. Mirkin Mark H. Mirkin · July 31, 2014
The public securities markets and the underwriters that lead biotech companies into them dictate a common capital structure suitable for IPOs, which structure almost always deviates starkly from the capital structure of the venture at inception and during its growth phase. Startups frequently commence corporate life structured as limited liability

Continue Reading…

Introducing a New Drug Into the Marketplace in the Lifecycle of a Pre-Sales Revenue Biotechnology Venture Destined for IPO Success

Insight Mark H. Mirkin Mark H. Mirkin · July 24, 2014
Mindful that this series of articles describes biotech ventures that are ripe for initial public offerings even before launching an income-producing drug product into the commercial market, the paramount objective for all such ventures is to manufacture drugs and commence marketing, sales and distribution thereof as soon as possible. As you read

Continue Reading…

Success Protecting Intellectual Property in the Lifecycle of a Pre-Sales Revenue Biotechnology Venture Destined for IPO

Insight Mark H. Mirkin Mark H. Mirkin · April 22, 2014
For a drug discovery start-up, patent protection of the intellectual property underlying the commercialization pursuit is critically important. If the company is a university or research institution spin-out that obtained licensed rights to intellectual property through a technology transfer, either the licensor or the licensee – as set

Continue Reading…

The FDA Drug Approval Process in the Lifecycle of a Pre-Sales Revenue Biotechnology Venture Destined for IPO Success

Insight Mark H. Mirkin Mark H. Mirkin · February 25, 2014
The U.S. Food & Drug Administration regulates new drug approvals in a process that is extremely thorough, lengthy and expensive. Regulations apply to a drug candidate’s product development phase, the approval process and after approval. Failure to comply could have serious business and financial con-sequences to a biotech venture,

Continue Reading…

Tech Transfers in the Lifecycle of a Pre-Sales Revenue Biotechnology Venture Destined for IPO Success

Insight Mark H. Mirkin Mark H. Mirkin · February 19, 2014
Many biotech ventures begin life as an invention conceived by a scientist/professor working in a laboratory at a federally-funded university or scientific institute. The intellectual property underlying such inventions is owned by the academic institution, a potentially valuable asset to be nurtured. Since enactment of the Bayh-Dole Act in 1980,

Continue Reading…